Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes

Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes

Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investiga...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fundamental & clinical pharmacology 2012, Vol.26 (SI 1), p.28-28
Hauptverfasser: Meillon, S., Brindisi, M-C., Vergès, B., Deglaire, Amélie, Brondel, L., Penicaud, L.
Format: Artikel
Sprache:eng
Schlagworte:
Biochemistry, Molecular Biology
Life Sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 28
container_issue SI 1
container_start_page 28
container_title Fundamental & clinical pharmacology
container_volume 26
creator Meillon, S.
Brindisi, M-C.
Vergès, B.
Deglaire, Amélie
Brondel, L.
Penicaud, L.
description Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investigate the impact of GLP-1 analogue Liraglutide on the liking and wanting component of the food reward system as well as on taste sensitivity in T2DM patients. Research design and methods: Thirty T2DM patients were studied before and after 3 months of daily Liraglutide treatment (1.2 mg). In each trial, blood samples were collected and body mass composition was analyzed by dual-energy X-ray absorptiometry. Liking, recalled liking and wanting for lipids, proteins and carbohydrates were assessed and detection thresholds for salt, sweet and bitter tastes were measured. Results: After three months of daily treatment with Liraglutide, T2DM patients had a significant decrease in hunger sensation (p
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00849252v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_00849252v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_00849252v13</originalsourceid><addsrcrecordid>eNqVjMuKwkAQAAdxwaj7D33dQ2Bm1DyOIj4OHvbgPbROZzNLMhPSvUL-XgV_YE8FRVETlZh1btPC6myqEp1neboqCzNTc-ZfrU2uTZao-jIQSkdB4DrC8fydGsCfGDwLdNH9tSjE0JB7qhsMxH0MTCAR6hgdYHAgyELAFNiLv3sZwQeQsSew4Dxe6XlYqo8aW6bPNxfq67C_7E5pg23VD77DYawi-uq0PVcvp3WxLu3G3s3qP-0DEZpLyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Meillon, S. ; Brindisi, M-C. ; Vergès, B. ; Deglaire, Amélie ; Brondel, L. ; Penicaud, L.</creator><creatorcontrib>Meillon, S. ; Brindisi, M-C. ; Vergès, B. ; Deglaire, Amélie ; Brondel, L. ; Penicaud, L.</creatorcontrib><description><![CDATA[Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investigate the impact of GLP-1 analogue Liraglutide on the liking and wanting component of the food reward system as well as on taste sensitivity in T2DM patients. Research design and methods: Thirty T2DM patients were studied before and after 3 months of daily Liraglutide treatment (1.2 mg). In each trial, blood samples were collected and body mass composition was analyzed by dual-energy X-ray absorptiometry. Liking, recalled liking and wanting for lipids, proteins and carbohydrates were assessed and detection thresholds for salt, sweet and bitter tastes were measured. Results: After three months of daily treatment with Liraglutide, T2DM patients had a significant decrease in hunger sensation (p<0.01), food intake (p<0.01) and weight (p<0.01) but not in the pleasure in eating. A reduction in plasma leptin (p<0.01) and ghrelin (p<0.01) levels was also observed. Liking (p=0.04), recalled liking (p=0.05) and wanting (p<0.01) for fatty foods were lowered by the treatment. Sensitivity to sweet taste was improved (p=0.04) whereas it remained unchanged for salty and bitter tastes. Conclusions: This is the first study to show a decrease in hedonic response for fatty foods and an increase in sweet taste sensitivity induced by GLP-1 analogues. These results are of interest in the understanding of weight loss mechanisms and cardiovascular risk improvement induced by GLP-1 analogues.]]></description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><language>eng</language><publisher>Wiley</publisher><subject>Biochemistry, Molecular Biology ; Life Sciences</subject><ispartof>Fundamental &amp; clinical pharmacology, 2012, Vol.26 (SI 1), p.28-28</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-8366-116X ; 0000-0001-8366-116X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,4010</link.rule.ids><backlink>$$Uhttps://institut-agro-rennes-angers.hal.science/hal-00849252$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Meillon, S.</creatorcontrib><creatorcontrib>Brindisi, M-C.</creatorcontrib><creatorcontrib>Vergès, B.</creatorcontrib><creatorcontrib>Deglaire, Amélie</creatorcontrib><creatorcontrib>Brondel, L.</creatorcontrib><creatorcontrib>Penicaud, L.</creatorcontrib><title>Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes</title><title>Fundamental &amp; clinical pharmacology</title><description><![CDATA[Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investigate the impact of GLP-1 analogue Liraglutide on the liking and wanting component of the food reward system as well as on taste sensitivity in T2DM patients. Research design and methods: Thirty T2DM patients were studied before and after 3 months of daily Liraglutide treatment (1.2 mg). In each trial, blood samples were collected and body mass composition was analyzed by dual-energy X-ray absorptiometry. Liking, recalled liking and wanting for lipids, proteins and carbohydrates were assessed and detection thresholds for salt, sweet and bitter tastes were measured. Results: After three months of daily treatment with Liraglutide, T2DM patients had a significant decrease in hunger sensation (p<0.01), food intake (p<0.01) and weight (p<0.01) but not in the pleasure in eating. A reduction in plasma leptin (p<0.01) and ghrelin (p<0.01) levels was also observed. Liking (p=0.04), recalled liking (p=0.05) and wanting (p<0.01) for fatty foods were lowered by the treatment. Sensitivity to sweet taste was improved (p=0.04) whereas it remained unchanged for salty and bitter tastes. Conclusions: This is the first study to show a decrease in hedonic response for fatty foods and an increase in sweet taste sensitivity induced by GLP-1 analogues. These results are of interest in the understanding of weight loss mechanisms and cardiovascular risk improvement induced by GLP-1 analogues.]]></description><subject>Biochemistry, Molecular Biology</subject><subject>Life Sciences</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqVjMuKwkAQAAdxwaj7D33dQ2Bm1DyOIj4OHvbgPbROZzNLMhPSvUL-XgV_YE8FRVETlZh1btPC6myqEp1neboqCzNTc-ZfrU2uTZao-jIQSkdB4DrC8fydGsCfGDwLdNH9tSjE0JB7qhsMxH0MTCAR6hgdYHAgyELAFNiLv3sZwQeQsSew4Dxe6XlYqo8aW6bPNxfq67C_7E5pg23VD77DYawi-uq0PVcvp3WxLu3G3s3qP-0DEZpLyQ</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Meillon, S.</creator><creator>Brindisi, M-C.</creator><creator>Vergès, B.</creator><creator>Deglaire, Amélie</creator><creator>Brondel, L.</creator><creator>Penicaud, L.</creator><general>Wiley</general><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-8366-116X</orcidid><orcidid>https://orcid.org/0000-0001-8366-116X</orcidid></search><sort><creationdate>2012</creationdate><title>Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes</title><author>Meillon, S. ; Brindisi, M-C. ; Vergès, B. ; Deglaire, Amélie ; Brondel, L. ; Penicaud, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_00849252v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biochemistry, Molecular Biology</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meillon, S.</creatorcontrib><creatorcontrib>Brindisi, M-C.</creatorcontrib><creatorcontrib>Vergès, B.</creatorcontrib><creatorcontrib>Deglaire, Amélie</creatorcontrib><creatorcontrib>Brondel, L.</creatorcontrib><creatorcontrib>Penicaud, L.</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Fundamental &amp; clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meillon, S.</au><au>Brindisi, M-C.</au><au>Vergès, B.</au><au>Deglaire, Amélie</au><au>Brondel, L.</au><au>Penicaud, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes</atitle><jtitle>Fundamental &amp; clinical pharmacology</jtitle><date>2012</date><risdate>2012</risdate><volume>26</volume><issue>SI 1</issue><spage>28</spage><epage>28</epage><pages>28-28</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract><![CDATA[Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investigate the impact of GLP-1 analogue Liraglutide on the liking and wanting component of the food reward system as well as on taste sensitivity in T2DM patients. Research design and methods: Thirty T2DM patients were studied before and after 3 months of daily Liraglutide treatment (1.2 mg). In each trial, blood samples were collected and body mass composition was analyzed by dual-energy X-ray absorptiometry. Liking, recalled liking and wanting for lipids, proteins and carbohydrates were assessed and detection thresholds for salt, sweet and bitter tastes were measured. Results: After three months of daily treatment with Liraglutide, T2DM patients had a significant decrease in hunger sensation (p<0.01), food intake (p<0.01) and weight (p<0.01) but not in the pleasure in eating. A reduction in plasma leptin (p<0.01) and ghrelin (p<0.01) levels was also observed. Liking (p=0.04), recalled liking (p=0.05) and wanting (p<0.01) for fatty foods were lowered by the treatment. Sensitivity to sweet taste was improved (p=0.04) whereas it remained unchanged for salty and bitter tastes. Conclusions: This is the first study to show a decrease in hedonic response for fatty foods and an increase in sweet taste sensitivity induced by GLP-1 analogues. These results are of interest in the understanding of weight loss mechanisms and cardiovascular risk improvement induced by GLP-1 analogues.]]></abstract><pub>Wiley</pub><orcidid>https://orcid.org/0000-0001-8366-116X</orcidid><orcidid>https://orcid.org/0000-0001-8366-116X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0767-3981
ispartof Fundamental & clinical pharmacology, 2012, Vol.26 (SI 1), p.28-28
issn 0767-3981
1472-8206
language eng
recordid cdi_hal_primary_oai_HAL_hal_00849252v1
source Wiley Online Library Journals Frontfile Complete
subjects Biochemistry, Molecular Biology
Life Sciences
title Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A38%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20by%20GLP-1%20agonist%20modulates%20hedonic%20response%20to%20food%20and%20taste%20sensitivity%20in%20type%202%20diabetes&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Meillon,%20S.&rft.date=2012&rft.volume=26&rft.issue=SI%201&rft.spage=28&rft.epage=28&rft.pages=28-28&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/&rft_dat=%3Chal%3Eoai_HAL_hal_00849252v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true